5AM Ventures - Company Portfolio

	Achaogen, an infectious disease therapeutics company founded out of The Scripps Research Institute, develops solutions to the problem of drug resistance.
	Alexza, a drug delivery company founded by Dr. Alejandro Zaffaroni, utilizes a novel technology that leverages the pharmacodynamics of existing therapies to rapidly deliver drugs locally and systemically through the lung. Went public in March 2006.
	Ambrx, a protein therapeutics company, exploits technology developed by Prof. Peter Schultz in the novel field of protein medicinal chemistry that enables the development of proteins with new and improved physical, chemical, and pharmacological properties.
	Anaphore, a protein therapeutics company, uses proprietary validated platforms to develop biologic-based therapeutics for immune-based disorders such as cancer and autoimmune diseases.
	Envoy, a platform CNS drug discovery company spun out of decades of work at the Rockefeller University, uses bacTRAP© technology to conduct detailed analysis of gene translational profiles in individual cell types in complex, multi-cellular organs.
	Flexion, in partnership with pharmaceutical and biotechnology companies, advances drug candidates through clinical Proof of Concept and, for those candidates demonstrating therapeutic potential, Flexion provides channels for the realization of commercial value.
	Igenica, a monoclonal-antibody discovery and development company, leverages innovative platform screening technologies to identify novel therapeutics for cancer.
	Ikaria, a fully-integrated critical care company originally founded around novel hibernation technology from Mark Roth, Ph.D., develops and commercializes products to treat high-risk, critically ill patients.
	Ilypsa, a spinout of Symyx Technologies (NASDAQ: SMMX), leveraged Symyx's existing high-throughput technologies to discover and develop new polymer-based therapeutics. Acquired by Amgen in July 2007.
INCLINE THERAPEUTICS	Incline, a hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system). Incline is financed by leading life science venture capital firms and led by a management team with significant pharmaceutical and medical device industry experience.
	KaloBios, a monoclonal antibody company, develops first- or best-in-class antibody therapeutics in the fields of autoimmunity, anti-infectives and oncology.
	Kalypsys, a spinout of the Genomics Institute of the Novartis Research Foundation, leverages robotics, cellular assays and high-throughput screening to develop compounds against cardiovascular/metabolic diseases, pain/inflammation and oncology.
	Marcadia, a peptide therapeutics company, leverages the work of Prof. Richard DiMarchi to develop a portfolio of novel therapeutics for metabolic diseases.
	Miikana, a clinically-driven oncology company founded out of the former Amgen Institute, develops small molecule therapeutics for cancer. Acquired by EntreMed in January 2006.
	Panomics (formerly Genospectra), a life science reagents company, develops novel cell-based assays and tools to enable multiplexed measurements of molecular events in a quantitative and scalable manner. Acquired by Affymetrix in December 2008.
	Pearl, a spinout of Nektar (NASDAQ: NKTR), develops products for the treatment and prevention of inflammatory, obstructive and allergic conditions in respiratory diseases.
	PhaseRx, a biopharmaceutical company, develops novel approaches to the delivery of siRNA and other macromolecules. The core delivery platform is based on polymer technology developed at the University of Washington.
	Pulmatrix, is discovering a new class of host-targeted therapies that pathogen independently treat, prevent and help control a broad range of respiratory infections and progressive respiratory diseases offering potential for individual therapies that treat serious diseases including influenza, rhinovirus, COPD, asthma and cystic fibrosis.
	Relypsa, a biopharmaceutical company spun out following the acquisition of Ilypsa by Amgen, leads the discovery and development of new non-absorbed polymeric drugs.
	Rennovia, an early stage chemical company, is developing processes to make high-value known chemicals derived from renewable bio sources that have both financial and green advantages.
	Semprus (formerly SteriCoat), a biomedical company, develops implantable and permanently-antimicrobial surface technology that is incorporated into medical devices. The intellectual property originates from the MIT lab of Robert Langer, Ph.D.
	Synosia, a drug development company, develops innovative treatments for disorders of the central nervous system.
	Variation, an innovative vaccine company, leverages bioinformatics to develop novel synthetic vaccines against highly variant pathogens.
	Viveve, is an early-stage company devoted to enhancing a woman's sexual health post-childbirth. We are developing a new, non-surgical procedure that is intended to increase the feeling of vaginal tightness, offering patients the potential for enhanced physical sensation during intercourse and improved sexual satisfaction.
	WaveRx, a medical device company, develops novel technologies for dermatological disorders of the nail.
	Wildcat Discovery, a biotechnology-based company, pioneers novel high-throughput technologies and methods to accelerate the discovery and development of advanced materials for industrial applications.